NTLA
Price
$6.66
Change
-$0.45 (-6.33%)
Updated
Apr 1, 03:38 PM (EDT)
Capitalization
835.39M
30 days until earnings call
RXRX
Price
$5.10
Change
-$0.19 (-3.59%)
Updated
Apr 1, 02:57 PM (EDT)
Capitalization
2.34B
36 days until earnings call
Ad is loading...

NTLA vs RXRX

Header iconNTLA vs RXRX Comparison
Open Charts NTLA vs RXRXBanner chart's image
Intellia Therapeutics
Price$6.66
Change-$0.45 (-6.33%)
Volume$5.21K
Capitalization835.39M
Recursion Pharmaceuticals
Price$5.10
Change-$0.19 (-3.59%)
Volume$19.63K
Capitalization2.34B
NTLA vs RXRX Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. RXRX commentary
Apr 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and RXRX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 01, 2025
Stock price -- (NTLA: $7.11 vs. RXRX: $5.29)
Brand notoriety: NTLA and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 202% vs. RXRX: 71%
Market capitalization -- NTLA: $835.39M vs. RXRX: $2.34B
NTLA [@Biotechnology] is valued at $835.39M. RXRX’s [@Biotechnology] market capitalization is $2.34B. The market cap for tickers in the [@Biotechnology] industry ranges from $304.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 0 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, both NTLA and RXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 4 TA indicator(s) are bullish while RXRX’s TA Score has 4 bullish TA indicator(s).

  • NTLA’s TA Score: 4 bullish, 6 bearish.
  • RXRX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both NTLA and RXRX are a bad buy in the short-term.

Price Growth

NTLA (@Biotechnology) experienced а -23.63% price change this week, while RXRX (@Biotechnology) price change was -22.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.65%. For the same industry, the average monthly price growth was -12.93%, and the average quarterly price growth was -11.94%.

Reported Earning Dates

NTLA is expected to report earnings on May 01, 2025.

RXRX is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-8.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.34B) has a higher market cap than NTLA($835M). RXRX YTD gains are higher at: -21.746 vs. NTLA (-39.022). RXRX has higher annual earnings (EBITDA): -426.72M vs. NTLA (-523.98M). NTLA (602M) and RXRX (594M) have equal amount of cash in the bank . RXRX has less debt than NTLA: RXRX (108M) vs NTLA (210M). RXRX (58.5M) and NTLA (57.9M) have equivalent revenues.
NTLARXRXNTLA / RXRX
Capitalization835M2.34B36%
EBITDA-523.98M-426.72M123%
Gain YTD-39.022-21.746179%
P/E RatioN/AN/A-
Revenue57.9M58.5M99%
Total Cash602M594M101%
Total Debt210M108M194%
FUNDAMENTALS RATINGS
NTLA: Fundamental Ratings
NTLA
OUTLOOK RATING
1..100
57
VALUATION
overvalued / fair valued / undervalued
1..100
25
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
94
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
NTLARXRX
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 9 days ago
79%
Bullish Trend 9 days ago
85%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
87%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EPGAX18.12N/A
N/A
Fidelity Advisor Equity Growth A
WBALX16.75N/A
N/A
Weitz Conservative Allocation-Inv Cl
DGSCX39.13N/A
N/A
Virtus KAR Global Small-Cap Inst
FBTDX106.53N/A
N/A
Franklin Biotechnology Discovery C
MDCIX15.63N/A
N/A
Madison Mid Cap I

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been closely correlated with CRSP. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
-8.95%
CRSP - RXRX
69%
Closely correlated
-8.00%
BEAM - RXRX
62%
Loosely correlated
-12.07%
NTLA - RXRX
58%
Loosely correlated
-11.90%
PRME - RXRX
56%
Loosely correlated
N/A
ABSI - RXRX
53%
Loosely correlated
-7.04%
More